Roche's souped-up breast cancer drug steps on FDA fast track

Roche got the inside track in its final lap toward FDA approval for the armed antibody T-DM1. A new approach to treating HER2-positive breast cancer, the antibody-drug conjugate is seen as a significant advance for patients. The FDA put T-DM1 up for priority review, with a decision due by Feb. 26. Report